Alzheimer’s disease (AD) is the most common cause of dementia and affects nearly 5.9 million adults in the United States. Behavioral/neuropsychiatric symptoms, such as agitation and aggression, are highly prevalent in patients with dementia. They lead to poor quality of life and represent leading causes for institutionalization.
Behavioral disturbances are highly prevalent in patients with dementia.
There are no FDA-approved treatments for the behavioral/neuropsychiatric symptoms. There is a large unmet medical need for safe and effective therapies to treat the behavioral symptoms in patients with AD and other dementias.